Eric Lefkofsky is an entrepreneur and the founder of Tempus. It’s a renowned cancer-fighting firm in Chicago since its launch in 2015. The company’s forte lies in understanding is a patient’s tumor better and come up with a suitable treatment to combat it. Today Tempus is on the front line in cancer treatment, aiming at expanding its services beyond cancer. According to Eric Lefkofsky, the company has come up with funding channels to support its expansion. With the help of other investors like Franklin Templeton, Baillie Gifford, and the NEA Nova Holding, Tempus has raised more than $620 million in less than five years of its existence. The company has employed over 1,000 employees and has expanded in other areas like cardiology, depression, and diabetes. Besides, Tempus has come up with a platform to analyze clinical data from the patient’s medical records.
This enables doctors to offer quality treatment to all patients. The company is now the most significant cancer clinical sequence carrying out over 160,000 samples yearly from various cancer facilities. Tempus has partnered with several research facilities and oncologists in providing services like genomic sequence and to carry out clinical trials. As Eric Lefkofsky states, the company’s major partners are the University of Chicago, Rush, and Northwestern University, where the institutions provide a sequence of 6,000-10,000, cancer patients per year. The company’s value has tremendously increased since it secured a slot in Chicago private companies valued over $1 billion. This creates no doubt that the company is taking the lead in health matters.
Be the first to reply